What is NeoMedix?
Founded in 1991 and headquartered in Tustin, California, NeoMedix Corporation specializes in the development, prototyping, and commercialization of advanced medical devices. The company is best known for its Trabectome technology, a pioneering device designed for the surgical treatment of glaucoma. With a robust operational footprint spanning multiple U.S. cities and an international presence in Germany, NeoMedix has established itself as a critical provider of specialized surgical tools. Its business model focuses on addressing chronic ocular conditions through innovation, maintaining a high standard of clinical efficacy that has sustained its operations for over three decades.
How much funding has NeoMedix raised?
NeoMedix has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in NeoMedix
PPP
Public-Private Partnership
What's next for NeoMedix?
With the recent influx of capital, NeoMedix is positioned to accelerate its commercialization efforts and potentially scale its international distribution networks. The company's late-stage status suggests a strategic pivot toward optimizing operational efficiencies and deepening its penetration in the global glaucoma treatment market. Future initiatives will likely focus on enhancing the clinical adoption of the Trabectome system and exploring adjacent opportunities within the ophthalmic surgical space. As the firm navigates this phase of expansion, the focus remains on maintaining its competitive edge through rigorous research and development, ensuring that its medical device portfolio continues to meet the evolving needs of healthcare providers and patients worldwide.
See full NeoMedix company page
